FAQ/Help |
Calendar |
Search |
Today's Posts |
08-30-2020, 01:45 PM | #1 | ||
|
|||
Member
|
Here is the latest on all the PD clinical trials for PD this year. I am too discouraged to read the paper but if someone wants to pick through and see if there is any good news, go to it.
Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2 2 - IOS Press A recently published research report - conducted by Parkinson's research advocates and the research team at The Cure Parkinson's Trust (CPT) – presents an encouraging and useful overview of the current pipeline of agents being clinically tested for the treatment of Parkinson’s. The investigators analysed a large number of clinical trials (145 studies were included in the analysis) - categorising them into the type of drug being tested and the stage of their clinical development - to highlight interesting trends in how the disease is being targeted and to stimulate discussion and engagement between the research and Parkinson’s patient communities. This report represents one of the first classifications and in-depth analysis of its kind in the Parkinson's clinical trials arena. |
||
Reply With Quote |
08-31-2020, 08:49 PM | #2 | ||
|
|||
Member
|
For anyone who may be time challenged, here is my overview of an overview from the American Parkinson Disease Association!
Categories covered: - Alpha-synuclein strategies – decreasing aggregation of alpha-synuclein: --- Alpha-synuclein antibodies (passive immunity); --- Alpha-synuclein vaccine (active immunity); --- Molecules that block alpha-synuclein. - Glucagon-like peptide-1 (GLP-1) agonist strategies – decreasing neuro-inflammation; - Glucocerebrosidase (GBA) – enhancing the cell’s lysosomal system; - LRRK2 strategies; - c-Abl kinase strategies – decreasing oxidative stress. The Future of Parkinson’s Disease Treatments | APDA |
||
Reply With Quote |
"Thanks for this!" says: | johnt (09-01-2020) |
09-01-2020, 08:04 AM | #3 | ||
|
|||
Senior Member
|
"For anyone who may be time challenged, here is my overview of an overview" of an overview: don't hold your breath.
I believe that anyone who has Parkinson's now is better off managing presently available and proven treatments. John
__________________
Born 1955. Diagnosed PD 2005. Meds 2010-Nov 2016: Stalevo(75 mg) x 4, ropinirole xl 16 mg, rasagiline 1 mg Current meds: Stalevo(75 mg) x 5, ropinirole xl 8 mg, rasagiline 1 mg |
||
Reply With Quote |
"Thanks for this!" says: | jeffreyn (09-01-2020) |
09-01-2020, 09:18 PM | #4 | ||
|
|||
Member
|
Agreed!
I realize now that my term "time challenged" can have other meanings. The meaning I intended was: "Anyone too busy to read the original article (or even the APDA overview article)". |
||
Reply With Quote |
"Thanks for this!" says: | johnt (09-03-2020) |
08-19-2021, 09:02 PM | #5 | ||
|
|||
Member
|
The 2021 version of the "clinical trials pipeline" document is now available.
If you don't have time to read the document, just have a look at Figure 1 - it's inspirational ! Parkinson’s Disease Drug Therapies in the Clinical Trial Pipeline: 2021 Update - IOS Press |
||
Reply With Quote |
08-20-2021, 09:54 PM | #6 | ||
|
|||
Member
|
There is also a PNT article about the document.
Clinical Trials of Parkinson's Treatments Robust Despite COVID-19 |
||
Reply With Quote |
Reply |
|
|
Similar Threads | ||||
Thread | Forum | |||